Navigation Links
Global Market for Minimally Invasive Vertebral Compression Fracture Treatments Will Reach $925 Million by 2022
Date:9/3/2014

BURLINGTON, Mass., Sept. 3, 2014 /PRNewswire/ -- Decision Resources Group finds that the global market for minimally invasive vertebral compression fracture (MIVCF) treatments will reach a value of $925 million by 2022, driven by an increasing prevalence of osteoporosis, which is largely the result of an aging population. In addition, marketing activity and positive clinical data will spur increasing use of these devices in the tumor and trauma indications, supporting overall procedure volumes.

Other key findings from Decision Resources Group's coverage of the global MIVCF treatment market:

  • Global price declines: Price competition and economic challenges will negatively impact average device prices. Financial concerns will be particularly evident in European countries such as Italy, where the effects of the eurozone crisis are still lingering.
  • Rapidly expanding revenues in Japan: The Japanese market will see the strongest revenue growth, driven by the recent reimbursement approval and subsequent rapid adoption of Medtronic's Kyphoplasty product in the vertebral augmentation segment.
  • Steady U.S. forecast: Despite issues with reimbursement that hindered procedure volume growth in 2013, the United States market will remain the largest but lowest growth market through 2022; currently this market represents approximately two-thirds of total global revenues.

Comments from Decision Resources Group Senior Analyst Brady Baker:

  • "Medtronic holds the majority of revenues in the global MIVCF treatment market, largely as a result of its stronghold in the vertebral augmentation space. Additional competitors will look to capture market share, however, by launching innovative and lower-cost products. For example, both CareFusion and DFINE have gained strong market shares by incorporating unique features and low price points into their product portfolios."

Comments from Decision Resources Group Analyst Valentina Lim:

  • "Poor or nonexistent reimbursement will limit overall revenue expansion in some markets. For example, unfavorable reimbursement for vertebroplasty—particularly in Australia and Japan—will somewhat limit growth in the Asia Pacific region."

Additional Resources:

About Decision Resources Group

Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group 
Christopher Comfort  
781-993-2597  
ccomfort@dresourcesgroup.com

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO


'/>"/>
SOURCE Decision Resources Group
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Bone Cement and Accessories Market Is Set to Expand from $630 Million in 2013 to Over $1 Billion by 2022
2. Cambrex To Present At Rodman & Renshaw 16th Annual Global Investment Conference
3. CytoSorbents to Present at the 2014 Rodman & Renshaw Annual Global Investment Conference
4. Isis Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
5. RXi Pharmaceuticals to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
6. Relmada Therapeutics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th, 2014
7. Infinity And AbbVie Announce Global Strategic Collaboration To Develop And Commercialize Duvelisib (IPI-145) In Oncology
8. Global Markets and Technologies for Molecular Imaging Devices
9. Bariatric Surgery: Global Markets for Services and Devices
10. Acute Heart Failure Global Clinical Trials Review, H2, 2014
11. Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... , May 20, 2016 The ... investors believe that the industry is not far from ... today ActiveWallSt.com featured the following four equities: Anacor Pharmaceuticals ... ATHX ), Aralez Pharmaceuticals Inc. (NASDAQ: ... INFI ). Sign up for your free trading ...
(Date:5/19/2016)... , May 19,2016 Cellvizio ... Digestive Disease Week Meeting and 91 st ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) ... platform, today announced that its Cellvizio platform is ... on gastroenterology during the month of May. The ...
(Date:5/19/2016)... , The data will be presented in ... The conclusions of the study point to a ... 90% of the m presenting duration ... of the patients had clinical benefit.     ... study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... Backed by decades ... for each job, ensuring the best suited solution to meet regulatory requirements. Their ... at their lab in Istanbul. , Metroloji Okulu specializes in MadgeTech’s line of ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... Jonathan (Jon) Otterstatter to its board of directors. Otterstatter is co-founder, president ... the development of technological innovations that lead to broad-based healthcare solutions. , “Jon ...
(Date:5/24/2016)... ... May 24, 2016 , ... WaterAid launched the #perioddrama campaign to mark Menstrual ... 1 billion women around the world who do not have access to a toilet, even ... US about their dread of #perioddrama. The (sometimes hilarious) results help shine a light on ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... patient Services To Begin In June , Aloria Health, specializing in a re-imagined, ... opening of Aloria Milwaukee, its first treatment facility for outpatient, day treatment and ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... tick-borne disease research and education, today announced that it has named Scott Santarella ... the Bonnie J. Addario Lung Cancer Foundation (ALCF) in San Francisco, where he ...
Breaking Medicine News(10 mins):